Patents by Inventor John Zuris

John Zuris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281941
    Abstract: Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • Publication number: 20220226503
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Application
    Filed: June 17, 2021
    Publication date: July 21, 2022
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • Patent number: 11370823
    Abstract: Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: June 28, 2022
    Assignees: Massachusetts Eye and Ear Infirmary, President and Fellows of Harvard College
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • Patent number: 11071790
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 27, 2021
    Assignees: Massachusetts Eye and Ear Infirmary, President and Fellows of Harvard College
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • Publication number: 20200299661
    Abstract: The present disclosure relates to CRISPR/Cpf1-related methods and components for editing a target nucleic acid sequence and/or modulating expression of a target nucleic acid sequence, as well as methods and compositions for evaluating such editing and/or modulation of expression.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 24, 2020
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Jennifer Gori, John Zuris, Hariharan Jayaram